Collegium Pharma (COLL) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
March 7, 2018 4:01 PM ESTXtampza ER prescriptions grew by 37% in the fourth quarterFDA Approval of sNDA, including Comparative OxyContin Data in labelExpanded product portfolio by licensing rights to commercialize Nucynta franchiseRevenue growth and strong balance sheet provide cash runway into 2020 Conference call scheduled for today at 4:30 p.m. ET
CANTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update.Â
... More